🇺🇸 FDA
Pipeline program

The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

Approved other active

Quick answer

The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial. for Chronic Obstructive Pulmonary Disease is a Approved program (other) at Pierre Fabre Médicament with 1 ClinicalTrials.gov record(s).

Program details

Company
Pierre Fabre Médicament
Indication
Chronic Obstructive Pulmonary Disease
Phase
Approved
Modality
other
Status
active

Clinical trials